Prof. Dr. Abdulkadir BAŞTÜRK

1. Psoas and pectoralis muscle indices and brown adipose tissue activity may be prognostic indicators in older patients with multiple myeloma

Yilmaz Kars M., Kars T. U., Cayci M., Bagci M., Cirik S., Gunay A., et al.

International Journal of Hematology , cilt.124, sa.2, ss.215-227, 2026 (SCI-Expanded, Scopus)

2. Real-World Utilization of Midostaurin in Combination with Intensive Chemotherapy for Patients with FLT3 Mutated Acute Myeloid Leukemia: A Multicenter Study

Seçilmiş S., Kabukçu Hacıoğlu S., HİNDİLERDEN F., Turgut B., Özatlı D., Akgün Çağlıyan G., et al.

Journal of Clinical Medicine , cilt.15, sa.2, 2026 (SCI-Expanded, Scopus)

3. Therapeutic potential of Aronia melanocarpa in the prevention of bleomycin-induced lung fibrosis in rats

Bağcı M., Kars T. U., Kozan H. İ., YILMAZ S., UÇAR S., OKAN OFLAMAZ A., et al.

Eurasian Journal of Medicine and Oncology , cilt.9, sa.4, ss.248-257, 2025 (ESCI, Scopus)

4. The role of heparin in autologous stem cell mobilization in patients with multiple myeloma

SARICI A., ERKURT M. A., YILMAZ S., Demircioglu S., BERBER İ., BAŞTÜRK A., et al.

Transfusion and Apheresis Science , cilt.64, sa.4, 2025 (SCI-Expanded, Scopus)

5. Fresh and cryopreserved stem cell transplantation in myeloma patients: Does it make a difference on transplant outcomes?

ERKURT M. A., YILMAZ S., NAMDAROĞLU S., Demircioglu S., SARICI A., Cirik S., et al.

Transfusion and Apheresis Science , cilt.64, sa.4, 2025 (SCI-Expanded, Scopus)

6. The comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma

Karakus A., Hatipoglu U., Katircilar Y., ERKURT M. A., YILMAZ S., Cagliyan G. A., et al.

Transfusion and Apheresis Science , cilt.64, sa.4, 2025 (SCI-Expanded, Scopus)

7. Does Wilms Tumour-1 Gene Mutation Affect Treatment Options and Response in Acute Myeloid Leukaemia?

YILMAZ S., Zorlu T., Cırık S., Hidayet E., Durdu A., Okumuş N., et al.

Acta Haematologica Oncologica Turcica , cilt.58, sa.1, ss.16-20, 2025 (Scopus, TRDizin)

8. The role of ruxolitinib in the management of acute GVHD

NAMDAROĞLU S., Hidayet E., Aydin M. S., ERKURT M. A., BERBER İ., Cinar O. E., et al.

Transfusion and Apheresis Science , cilt.64, sa.1, 2025 (SCI-Expanded, Scopus)

9. What should be the optimal dose of post-transplantation cyclophosphamide for GVHD prophylaxis in allogeneic stem cell transplantation?

Ulas T., NAMDAROĞLU S., Hindilerden I. Y., ERKURT M. A., Erer K., YİĞENOĞLU T. N., et al.

Transfusion and Apheresis Science , cilt.64, sa.1, 2025 (SCI-Expanded, Scopus)

10. Can Pseudothrombocytopenia be recognised at first look?

YILMAZ S., Daǧ M., KIZILARSLANOĞLU M. C., BAŞTÜRK A.

Medicine (United States) , cilt.102, sa.41, 2023 (SCI-Expanded, Scopus)

11. International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report

Özatlı D., Giden A. O., ERKURT M. A., KORKMAZ S., BAŞCI S., Ulas T., et al.

Transfusion and Apheresis Science , cilt.62, sa.2, 2023 (SCI-Expanded, Scopus)

12. The clinicopathological features and survival of Castleman disease: A multicenter Turkish study

Yildiz J., Bagci M., Sayin S., Kaya A., YILMAZ F. H., EKİNCİ O., et al.

European Review for Medical and Pharmacological Sciences , cilt.26, sa.4, ss.1131-1137, 2022 (SCI-Expanded, Scopus)

13. Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers

BAŞCI S., ATA N., ALTUNTAŞ F., YİĞENOĞLU T. N., DAL M. S., KORKMAZ S., et al.

Internal and Emergency Medicine , cilt.17, sa.1, ss.135-139, 2022 (SCI-Expanded, Scopus)

14. A multicenter retrospective analysis on therapeutic plasma exchange in immune thrombocytopenic purpura

BAŞTÜRK A., Sayin S., ERKURT M. A., SARICI A., Ekinci O., Kum A., et al.

Transfusion and Apheresis Science , cilt.60, sa.5, 2021 (SCI-Expanded, Scopus)

15. COVID-19 in hematopoietic cell transplant recipients

ALTUNTAŞ F., ATA N., YİĞENOĞLU T. N., BAŞCI S., DAL M. S., KORKMAZ S., et al.

Bone Marrow Transplantation , cilt.56, sa.4, ss.952-955, 2021 (SCI-Expanded, Scopus)

16. Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data Kronik Lenfositik Lösemili Hastalarda İbrutinib Tedavisinin Etkililiği ve Güvenilirliği: Gerçek Hayat Verilerinin Retrospektif Analizi

Tombak A., Tanrıkulu F. P., Durusoy S. S., DİNÇYÜREK H. D., KAYA E., ÜMİT E. G., et al.

Turkish Journal of Hematology , cilt.38, sa.4, ss.273-285, 2021 (SCI-Expanded, Scopus, TRDizin)

17. COVID-19 clinical course and blood groups: Turkish population-based study

Dal M. S., ATA N., ALTUNTAŞ F., BAŞCI S., YİĞENOĞLU T. N., KORKMAZ S., et al.

Turkish Journal of Medical Sciences , cilt.51, sa.4, ss.1659-1664, 2021 (SCI-Expanded, Scopus, TRDizin)

18. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

BAŞCI S., ATA N., ALTUNTAŞ F., YİĞENOĞLU T. N., DAL M. S., KORKMAZ S., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.7, ss.1676-1682, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

19. Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)

Tekgündüz E., Demirkan F., Vural F., GÖKER H., Özdoğu H., KİKİ İ., et al.

Transfusion and Apheresis Science , cilt.56, sa.6, ss.804-808, 2017 (SCI-Expanded, Scopus)

Prof. Dr. Abdulkadir BAŞTÜRK

Yayınlar & Eserler

1. Psoas and pectoralis muscle indices and brown adipose tissue activity may be prognostic indicators in older patients with multiple myeloma

2. Real-World Utilization of Midostaurin in Combination with Intensive Chemotherapy for Patients with FLT3 Mutated Acute Myeloid Leukemia: A Multicenter Study

3. Therapeutic potential of Aronia melanocarpa in the prevention of bleomycin-induced lung fibrosis in rats

4. The role of heparin in autologous stem cell mobilization in patients with multiple myeloma

5. Fresh and cryopreserved stem cell transplantation in myeloma patients: Does it make a difference on transplant outcomes?

6. The comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma

7. Does Wilms Tumour-1 Gene Mutation Affect Treatment Options and Response in Acute Myeloid Leukaemia?

8. The role of ruxolitinib in the management of acute GVHD

9. What should be the optimal dose of post-transplantation cyclophosphamide for GVHD prophylaxis in allogeneic stem cell transplantation?

10. Can Pseudothrombocytopenia be recognised at first look?

11. International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report

12. The clinicopathological features and survival of Castleman disease: A multicenter Turkish study

13. Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers

14. A multicenter retrospective analysis on therapeutic plasma exchange in immune thrombocytopenic purpura

15. COVID-19 in hematopoietic cell transplant recipients

16. Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data Kronik Lenfositik Lösemili Hastalarda İbrutinib Tedavisinin Etkililiği ve Güvenilirliği: Gerçek Hayat Verilerinin Retrospektif Analizi

17. COVID-19 clinical course and blood groups: Turkish population-based study

18. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

19. Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)

Yayın

Yayın (WoS)

Yayın (Scopus)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Atıf (TrDizin)

H-İndeks (TrDizin)

Atıf (Diğer Toplam)

Tez Danışmanlığı

Açık Erişim